Ocular begins patient enrolment in dexamethasone Phase II trial for dry eye disease
US-based biopharmaceutical firm Ocular Therapeutix has started patient enrolment in a Phase II clinical trial of sustained release dexamethasone (OTX-DP), an ophthalmic corticosteroid to treat inflammatory dry eye disease.